DexCom (DXCM) faces GLP-1 disruption as it targets non-insulin Type 2 CGM growth. Read here for a detailed invesment analysis ...

Insulet (PODD) stock and DexCom (DXCM) receive new Buy ratings from Deutsche Bank while Tandem Diabetes Care (TNDM) stock ...

Dexcom anticipates that the findings could drive a shift in the standard of care for type 2 diabetes patients who do not use ...

June 6 (Reuters) - Medical device maker Dexcom (DXCM.O), opens new tab said the use of its continuous glucose monitor, G7, led to improved blood sugar control in patients with type 2 diabetes not ...

Dexcom received FDA clearance for its first over-the-counter continuous glucose monitor, called Stelo. The device is intended for people with Type 2 diabetes who do not take insulin. · MedTech Dive · ...

Smartwatches may transform blood sugar tracking, but today’s advances depend on CGMs, AI, and regulated health tech ...

Following expanded FDA approval for pediatric patients, the over-the-counter Stelo continuous glucose monitor is adding AI ...

Every day there are new posts in a Facebook group — 89.5 thousand members strong — dedicated to Dexcom G7 issues and complaints. From inaccurate CGM readings and sensor failures to frustrating ...

CONTINUOUS GLUCOSE MONITORS are an important tool for people with diabetes. But if you recently bought a Dexcom continuous glucose monitor, you might want to double-check the label. You may be wearing ...

DexCom, Inc. DXCM recently announced positive results from its CONNECT randomized controlled trial, demonstrating that use of the Dexcom G7 continuous glucose monitoring (CGM) system significantly ...

Continuous glucose monitors have become popular among those who need to track their glucose levels because they're painless ...

AI may help smartwatches make glucose data more useful through better predictions, pattern detection, and personalized health ...